Created at	Source	Raw Value	Validated value
Jan. 29, 2021, 12:31 a.m.	usa	Change from Baseline in Antigen-Specific Cellular Immune Response;Change from Baseline in SARS-CoV-2 Spike Glycoprotein Antigen-Specific Binding Antibody Titers;Percentage of Participants with Administration (Injection) Site Reactions;Percentage of Participants with Adverse Events (AEs);Percentage of Participants with Adverse Events of Special Interest (AESIs)	Change from Baseline in Antigen-Specific Cellular Immune Response;Change from Baseline in SARS-CoV-2 Spike Glycoprotein Antigen-Specific Binding Antibody Titers;Percentage of Participants with Administration (Injection) Site Reactions;Percentage of Participants with Adverse Events (AEs);Percentage of Participants with Adverse Events of Special Interest (AESIs)
Jan. 17, 2021, 12:31 a.m.	usa	Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response;Change from Baseline in SARS-CoV-2 Spike Glycoprotein Antigen-Specific Binding Antibody Titers;Percentage of Participants with Administration (Injection) Site Reactions;Percentage of Participants with Adverse Events (AEs);Percentage of Participants with Adverse Events of Special Interest (AESIs)	Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response;Change from Baseline in SARS-CoV-2 Spike Glycoprotein Antigen-Specific Binding Antibody Titers;Percentage of Participants with Administration (Injection) Site Reactions;Percentage of Participants with Adverse Events (AEs);Percentage of Participants with Adverse Events of Special Interest (AESIs)
Oct. 26, 2020, 11:31 p.m.	usa	Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response;Percentage of Participants with Adverse Events of Special Interest (AESIs);Percentage of Participants with Administration (Injection) Site Reactions;Percentage of Participants with Adverse Events (AEs);Change from Baseline in Antigen-Specific Binding Antibody Titers	Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response;Percentage of Participants with Adverse Events of Special Interest (AESIs);Percentage of Participants with Administration (Injection) Site Reactions;Percentage of Participants with Adverse Events (AEs);Change from Baseline in Antigen-Specific Binding Antibody Titers